ABPI responds to Government's announcement of details for supporting pharmaceutical companies’ investments in developing drugs to tackle AMR infections

ABPI: “Patients can’t afford to wait” for AMR infections research

The Association of the British Pharmaceutical Industry (ABPI) has responded to the Government's announcement of further details for how it will support pharmaceutical companies’...
Gilead and Galapagos announce research and development collaboration.

SMC approves Ibrance for use within NHS Scotland

Pfizer has announced that the Scottish Medicines Consortium (SMC) has accepted Ibrance (palbociclib) for use within NHS Scotland for the treatment of hormone receptor...
NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis.

Gene silencing therapy for hereditary amyloidosis approved by NICE

NICE has approved a first-in-class gene silencing therapy for hereditary amyloidosis. RNA interference (RNAi) therapeutics company, Alnylam UK Limited has welcomed a decision from the...
SMC approves Darzalex for use as second-line treatment in certain multiple myeloma patients

SMC recommends Darzalex as second-line treatment for multiple myeloma

The Scottish Medicines Consortium (SMC) has recommended Darzalex® (daratumumab) plus bortezomib and dexamethasone as an option for treating relapsed multiple myeloma in people who...
Wasdell's new EU headquarters commences operations

Wasdell Group’s EU HQ commences operations

Outsourcing partner for the pharmaceutical industry, The Wasdell Group (Wasdell), has announced that its new state-of-the-art facility in Dundalk, Ireland has received its Manufacturer’s...
AstraZeneca to appeal NICE's osimertinib decision

AstraZeneca to appeal NICE’s osimertinib decision

AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...
ABPI Chief Executive announces retirement

ABPI Chief Executive announces retirement

The ABPI Chief Executive Mike Thompson, has announced that he is due to retire at the end of 2019. Mike joined the ABPI in March...
Life-extending lung cancer treatment, Vizimpro recommended on NHS as a first-line treatment for non-small-cell lung cancer

Vizimpro recommended on NHS for NSCLC – NICE

Life-extending lung cancer treatment, Vizimpro recommended on NHS as a first-line treatment for non-small-cell lung cancer. Dacomitinib (Vizimpro, Pfizer) has been recommended as a first-line...
LEO Pharma colleagues will undertake charity walk for National Eczema Society

LEO Pharma takes walk in aid of National Eczema Society

27 colleagues from LEO Pharma are taking on the challenge of walking a marathon (26.2 miles) along the Thames Path, from Henley to Windsor,...
Cemiplimab recommended in Cancer Drugs Fund

Cemiplimab recommended in Cancer Drugs Fund

Cemiplimab recommended in the Cancer Drugs Fund following draft guidance from the National Institute for Health and Care Excellence (NICE). NICE has issued draft guidance...

Latest articles

Patients to have a further drug combination option on Cancer Drugs Fund as NICE approves ribociclib with fulvestrant for breast cancer in draft guidance

NICE approves ribociclib with fulvestrant for breast cancer

Patients to have a further drug combination option on Cancer Drugs Fund as NICE approves ribociclib with fulvestrant for breast cancer in draft guidance. The positive...
new research into the relationship between sleep medication and dementia

New research highlights the relationship between sleep medication and dementia

New research presented at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles highlights the relationship between sleep medication and dementia. It examines the...
ViiV Healthcare showcasing innovation in HIV science at IAS 2019

ViiV Healthcare to showcase innovation in HIV science

ViiV Healthcare has announced that 20 abstracts from its portfolio of late-stage pipeline and authorised HIV treatments will be presented at the 10th International...

Popular articles

ViiV Healthcare showcasing innovation in HIV science at IAS 2019

ViiV Healthcare to showcase innovation in HIV science

ViiV Healthcare has announced that 20 abstracts from its portfolio of late-stage pipeline and authorised HIV treatments will be presented at the 10th International...
pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...

Driving patient centricity in patient-facing programmes

How one company created a core proposition which puts the patient first in all the work it does. All companies within the healthcare sector...
new research into the relationship between sleep medication and dementia

New research highlights the relationship between sleep medication and dementia

New research presented at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles highlights the relationship between sleep medication and dementia. It examines the...

Engaging patients earlier in clinical development

Successful patient engagement is essential to the clinical development process. How can companies get it right? Patient and public engagement in clinical research means that...